Ignite Creation Date:
2024-10-25 @ 7:57 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06558799
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-31
Brief Title:
LUNAR-4 Effect of Tumor Treating Fields TTFields 150 kHz Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer NSCLC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
LUNAR-4 Pilot Single Arm Open-Label Multinational Study of Tumor Treating Fields TTFields 150 kHz Concomitant With Pembrolizumab for the Treatment of Metastatic Non-Small Cell Lung Cancer NSCLC Previously Treated With a PD-1PD-L1 Inhibitor and Platinum-Based Chemotherapy
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LUNAR-4
Brief Summary:
The purpose of the study is to test the effectiveness and safety of TTFields therapy delivered using the NovoTTF-200T device concomitant with pembrolizumab in subjects with metastatic NSCLC previously treated with a PD-1PD-L1 inhibitor and platinum-based chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None